<DOC>
	<DOCNO>NCT02536664</DOCNO>
	<brief_summary>It non-interventional study duration approximately 24 month per participant investigate therapeutic efficiency , safety treatment regimens Rituximab maintenance therapy daily routine participant previously untreated , relapse refractory cluster differentiation 20 ( CD20 ) -positive follicular lymphoma ( FL ) clinical practice .</brief_summary>
	<brief_title>Non-Interventional Study Examine Rituximab Treatment Follicular Lymphoma Participants</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 18 year Previously untreated , relapse refractory CD 20positive FL Responding rituximab contain induction therapy ( complete response [ CR ] partial response [ PR ] ) To receive rituximab maintenance therapy ( decision take doctor prior independent noninterventional study ) No ineligibility rituximab Not Applicable ( NA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>